Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Andrew H. Wei, Nigel H. Russell et al.|Blood|2022Cited by 83
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Charlotte S. Wilhelm-Benartzi et al.|Blood|2024Cited by 78
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remissionJad Othman, Nigel H. Russell, Richard Dillon et al.|Blood|2024Cited by 75
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Richard Dillon, Steven Knapper et al.|The Lancet Haematology|2025Cited by 9